A White House decision on pharma tariffs, tied to a national security probe under Section 232, is delayed again as the administration prioritizes a semiconductor review and a U.S.-Russia summit. Trump's plan could see duties rise to 250%, with exemptions possible under select trade deals. Drugmakers warn tariffs risk raising costs and hampering price-cut efforts.